Back to top
more

Praxis Precision Medicines (PRAX)

(Delayed Data from NSDQ)

$50.88 USD

50.88
327,260

+0.89 (1.78%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

by Zacks Equity Research

JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -7.81% and 37.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 15.08% and 31.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ekta Bagri headshot

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

by Ekta Bagri

Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.

Praxis (PRAX) Surges on Positive Epilepsy Study Results

by Zacks Equity Research

Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.

What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Praxis Precision Medicines, Inc. (PRAX) delivered earnings and revenue surprises of 5.71% and 71.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Praxis Precision Medicines, Inc. (PRAX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Praxis Precision Medicines, Inc. (PRAX) points to a 495% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Best Momentum Stocks to Buy for October 11th

by Zacks Equity Research

PBF, PRAX and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 11, 2023.

New Strong Buy Stocks for October 11th

by Zacks Equity Research

PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.

Praxis (PRAX) Tanks on Negative Data From Depression Study

by Zacks Equity Research

Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.